Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Opus Genetics Inc

IRD ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$3.61

▼ -2.96%

Market Cap $300.34M · Vol 136.56K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$300.34M

Small Cap

Div Yield

N/A

EPS Growth

-24.10%

YoY

RSI (14)

59.03

Momentum

Beta

0.57

vs Market

52W High

$5.81

37.87% below

52W Low

$1.11

225.23% above

Volume

136.56K

Avg 227.87K

P/B

9.15

Price-to-book

ROE

N/A

Return on equity

Free Float

86.62%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Opus Genetics Inc (IRD) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IRD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.37%

+1.40%

-27.36%

-0.82%

YTD

+79.60%

+205.93%

-13.84%

-20.66%

Financials & Valuation

TTM · Annual

Total Revenue	$14.20M
Net Income	$-49,591,000.00
Revenue Growth (YoY)	-73.80%
Gross Margin	100.00%
Operating Margin	-257.11%
Net Profit Margin	-349.33%
ROE	N/A
ROA · ROIC	-113.86% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	8.81
P/B	9.15
P/FCF	N/A
EPS Growth	-24.10%
Outstanding Shares	83.20M

Technical Indicators

50-Day SMA	$3.77
200-Day SMA	$3.54
RSI (14)	59.03
Beta	0.57
52-Week High	$5.81
52-Week Low	$1.11

Volume Today	136.56K
Avg Daily Volume (30D)	227.87K
Relative Volume	0.60x
Volatility (10D)	41.62
Volatility (30D)	62.61
Free Float	86.62%

Analyst Consensus

BUY

Current Price $3.61

Mean Target $10.47

52W Low$1.11 52W High$5.81

Current

Target

$1.11 $5.81

Current Analyst target

+190.13% upside potential · 19 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SC04V7

ISINUS67577R1023

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.